La chaîne d'options affiche les données clés des options sur actions de Captivision à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Captivision..

Captivision (NASDAQ:CAPT) Stock, Chaîne d'Options

Captivision Inc Formerly Glaam Co Ltd is engaged in manufacturing, installing, and selling LED display G-Glass. G-Glass is an integrated ICT product that has the basic characteristics of transparent glass but can display media images at the same time. It implements media images through the glass surface while preserving the features of clear and transparent glass. G-Glass is the world's first IT building material that can be applied to various places where glass is used.

On July 1, 2025, Advent Technologies Holdings, Inc. (the "Company") entered into a settlement agreement and release (the "Settlement Agreement") with F.E.R. fischer Edelstahlrohre GmbH ("Fischer" and, together with the Company, the "Parties"). The Settlement Agreement was executed to resolve a previously disclosed dispute that arose in connection with that certain share purchase agreement entered into by the Parties on or about June 25, 2021 (the "Purchase Agreement"), with Fischer alleging the Company failed to make payment of the consideration due under the Purchase Agreement in full as of the date of closing under the Purchase Agreement.
&nbsp;
In February 2025, the Parties met to discuss the possibility of a settlement and the framework for such a settlement, and on July 1, 2025, the Parties finalized and executed the Settlement Agreement.
&nbsp;
Pursuant to the terms of the Settlement Agreement, the Company has agreed to pay Fischer €5,366,625.55 with such payment to be made in installments beginning on September 1, 2025. The Company will be entitled to a reduced settlement amount totaling €4,366,625.55 if payment is made by no later than June 30, 2026. In exchange for such reduced settlement amount, both Parties agreed to a mutual release of claims against the other Party.

News

Legal

Advent Technologies Reaches ~€5.37 Million Settlement with Fischer Over Share Purchase Dispute, May Pay Reduced ~€4.37 Million if Settled By June 2026

Bill Ackman is best known for his <a href="https://www.benzinga.com/news/management/25/05/45456642/bill-ackman-loads-up-on-uber-dumps-nike-in-major-q1-portfolio-rebalance">large investments in companies</a> that can lead to activist battles. The investor is now ready to take a break from the stock market to participate in a sports competition.
What Happened: Ackman and<a href="https://www.benzinga.com/topic/tennis"> professional tennis player</a> Jack Sock will play doubles in the upcoming Hall of Fame Open in Rhode Island.
Ackman <a href="https://x.com/BillAckman/status/1940471542690840776">shared </a>the news on X, saying that "fate intervened," as he was initially scheduled to play doubles in an ATP tournament with Nick Kyrigos, who recently became injured.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">A tennis update. I met <a href="https://twitter.com/NickKyrgios?ref_src=twsrc%5Etfw">@NickKyrgios</a> on <a href="https://twitter.com/X?ref_src=twsrc%5Etfw">@X</a> and he proposed we play an ATP tournament together. Unfortunately, Nick got injured so our doubles hopes have been delayed, but fortunately fate intervened. <a href="https://twitter.com/JackSock?ref_src=twsrc%5Etfw">@JackSock</a> managed to get a wildcard into the <a href="https://twitter.com/TennisHalloFame?ref_src=twsrc%5Etfw">@TennisHalloFame</a> Hall of Fame Open… <a href="https://t.co/YR0IDQsi17">https://t.co/YR0IDQsi17</a>
&mdash; Bill Ackman (@BillAckman) <a href="https://twitter.com/BillAckman/status/1940471542690840776?ref_src=twsrc%5Etfw">July 2, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The Hall of Fame Open is an ATP Tour Challenger and WTA 124 Event.
Ackman and Sock will begin <a href="https://www.halloffameopen.com/en/tickets/buy-tickets">matches </a>Tuesday, July 8.
The Pershing Square Capital Management CEO encouraged his social media followers to come cheer the duo on and visit the Hall of Fame. Ackman said he could be one of the oldest people in tennis history at the age of 59 to win ATP points if they win the tournament.
"I am playing the best tennis of my life and Jack is one of the greatest doubles players ever," Ackman said.
The hedge funder said they start practice for the tournament on Friday and he thinks they have a shot at winning given Sock's career history in doubles and major tournament victories.
"You never know," Ackman said. He told an X user that he was a "decent high school player" for tennis, but not good enough to later make a college team so he did Varsity Crew.
"I took up the game 21 years ago and have taken it seriously for the last decade."
Sock has a career 210-101 record in doubles with 17 titles won. 
Read Also: <a href="https://www.benzinga.com/etfs/specialty-etfs/25/06/45730063/new-etfs-let-investors-mirror-buffett-ackman-burrys-top-stock-trades">New ETFs Let Investors Mirror Buffett, Ackman, Burry&#8217;s Top Stock Trades</a>
Why It's Important: While it's certainly fun for Ackman to participate in a major tennis tournament, the story underscores the perks of fame and social media.
After Ackman shared a video of a tennis match featuring Kyrgios and Novak Djokovic, Kyrgios offered the billionaire a tennis lesson.
Kyrgios also proposed to Ackman that they could take part in a tournament together and win.
"The power of X," Ackman added, citing how the social media platform facilitated their interaction.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/02/43506109/bill-ackman-sends-unitedhealth-stock-lower-with-deleted-tweet-heres-what-he-said">Bill Ackman Sends UnitedHealth Stock Lower With Deleted Tweet: Here&#8217;s What He Said</a></li>
</ul>
Image: Shutterstock

Social Media

Sports

General

Bill Ackman Swaps Wall Street For Tennis Court—And He Is Playing To Win: 'You Never Know'

Shares of SoundHound AI Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) traded slightly lower on Thursday, following a surge that saw the stock gain approximately 30% during the second quarter. This impressive run comes amid a 10% increase over the trailing week, signaling <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46231882/whats-going-on-with-soundhound-ai-soun-stock-3">strong investor interest</a> in the voice AI innovator.
What To Know: Potentially fueling this optimism is a number of bullish analyst ratings. Piper Sandler recently initiated coverage with a $12 price target, while Wedbush and HC Wainwright reiterated their positive outlooks, setting targets of $15 and $18, respectively.
This <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46178429/soundhound-stock-has-risen-over-the-past-three-months-whats-going-on">confidence</a> stems from the company&#8217;s robust performance, including a remarkable 151% year-over-year revenue increase in the first quarter. Looking ahead, SoundHound has forecast full-year revenue to come in between $157 million and $177 million.
The broader adoption of artificial intelligence in the restaurant industry is a significant tailwind for the company. As major chains like McDonald's, Dine Brands and Yum Brands increasingly integrate AI for operational efficiency and customer service, SoundHound&#8217;s conversational AI technology is viewed as a key enabler for 2025.
Investors are now eagerly awaiting the company&#8217;s second-quarter results, which are anticipated in early August. Current analyst forecasts project quarterly revenue of $32.88 million.
Benzinga Edge Rankings: Based on the latest Benzinga Edge stock rankings, SoundHound presents a mixed profile based on the available metrics. The stock demonstrates exceptional strength in one key area, scoring a 94.49 for Momentum, suggesting strong recent performance and investor interest.
However, it receives a very low score of 7.27 for Value, indicating that it may be considered overvalued based on its underlying financial fundamentals.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, SoundHound shares closed Thursday down 1.42% at $11.09. The stock has a 52-week high of $24.98 and a 52-week low of $3.87.
Read Also: <a href="https://www.benzinga.com/etfs/new-etfs/25/07/46203728/quantum-ai-nuclear-three-frontiers-one-launchpad-powered-by-defiance-etfs">Quantum, AI, Nuclear: Three Frontiers, One Launchpad Powered By Defiance ETFs</a>
<h2 class="wp-block-heading">How To Buy SOUN Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in SoundHound AI&#8217;s case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Image: Shutterstock

SOUN

What's Going On With SoundHound AI (SOUN) Shares Today?

Alibaba Group Holding Limited (NYSE: BABA and HKEX: 9988 (HKD Counter) and 89988 (RMB Counter), "Alibaba," "Alibaba Group" or the "Company") today announced the pricing of its private offering (the "Bond Offering") of HK$12.023 billion aggregate principal amount of Zero Coupon Exchangeable Bonds due 2032 (the "Bonds") by reference to the ordinary shares of Alibaba Health Information Technology Limited ("Alibaba Health") that are listed on The Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange") (HKEX: 00241) ("AH Shares"). The Bonds were offered to certain non-U.S. persons in offshore transactions outside the United States in reliance on Regulation S under the U.S. Securities Act of 1933, as amended (the "Securities Act"). The Bond Offering is expected to close on July 9, 2025, subject to customary closing conditions.
When issued, the Bonds will be unsecured and unsubordinated obligations of Alibaba Group. The Bonds will not bear regular interest. The Bonds will mature on July 9, 2032, unless redeemed, exchanged or purchased in accordance with their terms prior to such date.

Offerings

BABA

Alibaba Group Prices Private Offering Of HK$12.023 Billion Aggregate Principal Amount Of Zero Coupon Exchangeable Bonds Due 2032

NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) stock reached another all-time high on Thursday, solidifying its position as the world&#8217;s most valuable company with a market capitalization of $3.89 trillion. Here&#8217;s what investors <a href="https://www.benzinga.com/quote/NVDA/news">need to know</a>. 
What To Know: Nvidia&#8217;s surge Thursday came as U.S. stocks broadly rallied to <a href="https://www.benzinga.com/markets/equities/25/07/46251714/wall-street-today-stock-market-news-thursday-nvidia">new records</a>, fueled by stronger-than-expected labor market data that eased recession concerns. The S&amp;P 500 was approaching 6,300, and the Nasdaq-100 climbed to 22,860. Tech stocks, particularly the &#8220;Magnificent Seven,&#8221; were leading the charge.
Industry experts, like Wedbush Securities&#8217; Dan Ives, anticipate Nvidia and Microsoft could be the <a href="https://www.benzinga.com/markets/tech/25/07/46188671/nvidia-microsoft-on-track-to-achieve-4-trillion-market-cap-says-analyst-dan-ives-tech-bull-market-is-still-early">first companies</a> to hit a $4 trillion market cap this summer, potentially reaching $5 trillion within the next 18 months.
This optimistic outlook is driven by relentless innovation and significant investments in AI infrastructure, with both companies deemed &#8220;foundational pieces&#8221; of the ongoing AI revolution.
Further bolstering the semiconductor sector, the U.S. Senate and House <a href="https://www.benzinga.com/markets/equities/25/07/46251714/wall-street-today-stock-market-news-thursday-nvidia">passed</a> the &#8220;One Big Beautiful Bill,&#8221; which includes an increased investment tax credit for chip manufacturers, raising it from 25% to 35% for facilities expanding domestic production by 2026.
This legislative support, alongside <a href="https://www.benzinga.com/markets/tech/25/07/46230357/nvidia-taiwan-semiconductor-broadcom-drive-chip-stocks-to-a-golden-cross-will-history-repeat-with-145-rally">strong technical indicators</a> like the VanEck Semiconductor ETF (SMH) forming a &#8220;Golden Cross,&#8221; suggests continued bullish momentum for chipmakers. Nvidia, comprising over 21% of the SMH, is poised to benefit significantly from these favorable conditions and the burgeoning demand for AI.
Benzinga Edge Rankings: <a href="http://benzinga.grsm.io/register174">Benzinga Edge</a> data for Nvidia reveals a strong performance across key metrics. The stock boasts a high Growth score of 98.59, indicating robust expansion. 
Momentum is also significant at 78.44, suggesting a strong upward trend. However, Value is considerably lower at 6.92, implying the stock may be expensive relative to its fundamentals.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, Nvidia shares closed higher by 1.33% to $159.34 Thursday afternoon. Shares are higher by some 12.8% over the trailing month. The stock hit a 52-week high of $160.98 on Thursday, and has a 52-week low of $86.62.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46252007/coreweave-stock-rallied-on-thursday-what-happened">CoreWeave Stock Rallied On Thursday: What Happened?</a>
<h2 class="wp-block-heading">How To Buy NVDA Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Nvidia&#8217;s case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Image: Shutterstock

Movers

NVDA

Nvidia Stock Hits New All-Time Highs: What's Driving The Record-Breaking Run?

As the cost of college in the U.S. continues to surge, many parents are resorting to drastic financial strategies—including pausing retirement contributions, liquidating investments, and taking second jobs—to spare their children from taking on student debt.
In a <a href="https://investor.citizensbank.com/about-us/newsroom/latest-news/2025/2025-06-24.aspx">survey</a> commissioned by Citizens Bank and conducted by Researchscape, 61% of parents said they need to go beyond traditional college financing options, such as 529 savings plans and federal loans, to bridge the financial gap. Of the 1,000 respondents surveyed, 19% reported taking on a second job, 30% had borrowed against their 401(k) or withdrawn personal funds, and 26% paused investing altogether. Some said they cut back on vacations or major purchases.
Meanwhile, 62% of parents said they expect to delay their retirement to help cover their children's college education costs.
Don't Miss:
<ul class="wp-block-list">
<li>Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs — <a href="https://www.benzinga.com/money/americans-spend-1000-per-year-on-plastic-water-bottles-kara-pod-gives-you-clean-drinking-water-by-pulling-moisture-from-the-air">And You Can Invest At Just $6.37/Share</a></li>
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation. </a></li>
</ul>
<h2 class="wp-block-heading">College Costs Are Surging</h2>
The Education Data Initiative <a href="https://educationdata.org/college-tuition-inflation-rate">reports</a> that the average annual tuition at a public four-year college has risen 40 times since 1963. Between 2010 and 2023, tuition at four-year public universities jumped over 36%. Another EDI&nbsp; <a href="https://educationdata.org/average-cost-of-college">report</a> estimates the average annual cost of college—including tuition, room and board, fees, and supplies—at about $38,000.
"Compared to just a few years ago, the pressure has increased due to rising tuition, inflation, and greater uncertainty around future costs," Tony Durkan, vice president and head of 529 college savings at Fidelity, told <a href="https://fortune.com/2025/06/25/parents-retirement-second-jobs-afford-college/">Fortune</a>. "Many families are still underprepared, often relying on rough estimates rather than clear savings goals."
<h2 class="wp-block-heading">Emotional Decisions, Financial Consequences</h2>
Pam Krueger, investment advisor and founder of Wealthramp, told Fortune that she's seen a growing number of parents refinancing homes, pulling money from retirement, or juggling extra jobs to manage college expenses.
"It's coming from a place of love and a desire to protect their kids from the burden of student debt—but it's also very risky," Krueger said. "These choices can set parents back in a way that's really hard to recover from."
Trending: Tired of Grid Failures and Charging Deserts? This Startup Has a Solar Fix and $25M+ in Sales — <a href="https://www.benzinga.com/money/meet-the-company-seeking-to-give-americans-energy-independence-and-learn-how-you-can-become-an-early-investor">Now Raising at $3/Share</a>
Krueger added that many families make college decisions based on acceptance letters—not finances. Citizens Bank's survey results support this, showing that 20% of parents focused solely on getting their child into college without thinking about how to pay for it.
The topic also remains sensitive: nearly half of the parents surveyed said they'd rather talk to their child about drugs or alcohol than college costs.
<h2 class="wp-block-heading">Better Ways To Prepare</h2>
Durkan told Fortune that starting early with a 529 plan can provide significant long-term benefits. These tax-advantaged accounts allow for tuition savings and can be reassigned to other family members if unused.
"The earlier you begin saving, the more time your money has to grow through compounding," Durkan said. "Even small, regular contributions can add up significantly over time."
Krueger recommends open conversations with children—particularly in high school—about what's realistic, including considering schools with strong merit aid programs and transparent pricing.
"Sometimes the ‘big name' school isn't the best financial fit—and that's okay," Krueger told Fortune.
See Also: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. <a href="https://www.benzinga.com/money/this-company-may-have-found-a-way-to-treat-cancer-by-tricking-the-bodys-immune-system-and-early-studies-show-some-promise-find-out-how-you-can-invest-in-the-future-of-cancer-treatment">Back a bold new approach to cancer treatment with high-growth potential.</a>
<h2 class="wp-block-heading">Starting Late? Plan Strategically</h2>
College Planning Experts CEO Brian Safdari told Fortune that late-starting families should focus on applying for aid, reallocating investments, and estimating true out-of-pocket costs.
"Even private colleges with sticker prices over $95,000 per year may offer enough aid to cost less than a public school," Safdari said. But he also emphasized that gaps will likely remain.
"The expected cost minus savings minus free money will likely still leave a gap," Safdari said. "Once we have that number, we can start figuring out how to fund it over four years, while minimizing student debt and leaving enough money to retire."
Read Next: Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a>
Image: Shutterstock

Personal Finance

From 401(k) Loans to Side Hustles: The Extreme Measures Parents Take to Avoid Student Debt

With the S&amp;P 500 trading above 6,200 points and U.S. equities cruising into the July 4 holiday at all-time highs, long-term valuation <a href="https://www.benzinga.com/news/econ-s">metrics are sounding alarms. </a>
The so-called Buffett Indicator, a popular long-term valuation tool among traditional investors, has surged to its most extreme reading ever.
Yet, that doesn't mean it's time to panic and dump your stocks overnight.
<h2 class="wp-block-heading">What Is The Buffett Indicator?</h2>
Named after Berkshire Hathaway's Warren Buffett, the indicator measures the total value of the U.S. stock market relative to the country's gross domestic product.
It provides a broad snapshot of how inflated equities may be versus the actual size of the economy.
As a legendary investor, Buffett helped popularize the indicator by endorsing it as a key gauge of stock market valuations. In a 2001 interview, he called it "probably the best single measure of where valuations stand at any given moment."
As of July 3, the indicator shows a 207% ratio between the total U.S. stock market value and gross domestic product (GDP), according to the version tracking the Wilshire 5000 index, which covers nearly all publicly traded U.S. equities.
That means the market is worth more than double the size of the U.S. economy. A narrower version focused on the S&amp;P 500 vs. GDP stands at 176%, also hitting new record highs. 
In theory, valuations this rich should precede poor future returns, or even worse, sharp pullbacks.
It might sound worrisome, but here's why that's not the full story.
<h2 class="wp-block-heading">The Buffett Indicator Says Sell, But Timing The Market Top Is A Different Game</h2>
This indicator has been flashing overvaluation for years, and yet markets have continued to rise. 
Since January 2017, the S&amp;P 500 – as tracked by the Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) – has gained nearly 170% –&nbsp;excluding dividends –&nbsp;despite the Buffett Indicator staying above 100% almost the entire time. 
Only during brief dips in December 2018 and March 2020 did it temporarily retreat below that mark.
Investors who exited the market based solely on this signal missed a powerful bull run fueled by low interest rates, strong corporate earnings and massive fiscal support.
Most strikingly, since October 2023, the S&amp;P 500's valuation relative to GDP has remained above 125%, yet the index has added an impressive 50% gain in less than two years.
So why does the Buffett Indicator seem to be losing influence? In today&#8217;s market environment, valuation metrics alone haven't been reliable sell signals.
Real interest rates remain historically low, keeping borrowing costs manageable and supporting risk assets. At the same time, persistent fiscal spending continues to inject demand and liquidity into the economy. 
The dominance of large-cap tech companies has led to greater earnings concentration, which in turn fuels stock valuations.
That said, dismissing the Buffett signal entirely could be just as risky. While it hasn't been reliable for short-term market timing, extreme valuations have historically led to longer-term mean reversion, even if it doesn't happen immediately.
<h3 class="wp-block-heading">Chart: The Market Looks Expensive By Buffett's Standards – But That Hasn't Stopped The Rally Yet</h3>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="529" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03144551/image-48-1024x529.png" alt="" class="wp-image-972561" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03144551/image-48-1024x529.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03144551/image-48-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03144551/image-48-768x397.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03144551/image-48-1536x794.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03144551/image-48-2048x1059.png 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46251714/wall-street-today-stock-market-news-thursday-nvidia">Wall Street Soars To New Highs, Magnificent 7 Top $18 Trillion: What&#8217;s Moving Markets Thursday? </a></li>
</ul>
Photo: Photo Agency On Shutterstock.com

Equities

Large Cap

Broad U.S. Equity ETFs

Econ #s

Economics

ETFs

This Indicator Made Warren Buffett Famous — But It's Been Wrong About The Market For Years

Mark Cuban and Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk <a href="https://www.benzinga.com/general/social-media/24/12/42566461/mark-cuban-says-this-is-the-holy-grail-that-makes-bluesky-better-than-musks-x-platform">may not agree on everything </a>these days, except, perhaps, the potential for a viable third political party. But one thing they do share is the number of people who admire them.
What Happened: Musk and Cuban are both examples of <a href="https://www.benzinga.com/news/education/25/06/46157568/happy-birthday-elon-musk-54-facts-and-figures-about-tesla-spacex-ceo-on-his-54th-birthday">the entrepreneurial spirit</a> that Americans can use to achieve great things through hard work and perseverance, such as creating businesses and becoming extremely wealthy.
While Musk and Cuban created companies in different sectors, they share several commonalities, such as rewarding loyal early employees and adopting a hands-on management style.
The similarities and success could be why Musk and Cuban scored so well in a recent Benzinga poll asking about who would be the best business mentor. The other options in the poll were NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) CEO Jensen Huang, Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) CEO Mark Zuckerberg and Amazon.com Inc founder Jeff Bezos.
"Of the following, who would you be most likely to pick as your business mentor?" Benzinga asked.
The results were:
<ul class="wp-block-list">
<li>Elon Musk: 36%</li>
<li>Mark Cuban: 30%</li>
<li>Jensen Huang: 23%</li>
<li>Mark Zuckerberg: 8%</li>
<li>Jeff Bezos: 3%</li>
</ul>
The poll found that Musk was the top choice for a potential business mentor — a result likely tied to his reputation as the world's richest person and his relentless work ethic, which often involves sacrificing sleep to focus on his ventures.
Ranking second was Cuban with 30% of the vote. Cuban has been someone that investors and entrepreneurs have looked up to for years thanks to his appearances on "Shark Tank" and being very public with his ownership and running of the NBA's Dallas Mavericks.
Huang ranked third — a testament to the success he's achieved at Nvidia, the company he famously co-founded in a Denny's booth.
Zuckerberg and Bezos scored the lowest totals in the poll.
You may not be a billionaire like Mark Cuban, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/46157351/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-71">check out five stocks flying under the radar that deserve your attention.</a>
Why It's Important: Musk winning the poll isn't likely a surprise given the huge fandom he has thanks to leadership roles at Tesla, SpaceX, xAI and other companies. Musk is the most followed person on the social media platform X.
These days, Musk is often viewed as one of the best entrepreneurs and visionaries of the last 100 years. While some people may disagree with Musk politically or over ideals, they often respect the work he has done to forever change sectors like electric vehicles, clean energy and space exploration.
Cuban's role on "Shark Tank," which began in season 2 and <a href="https://www.benzinga.com/general/entertainment/24/10/41271567/mark-cuban-reflects-on-shark-tanks-enduring-success-the-american-dream-is-alive-and-well">recently came to an end</a>, has helped him gain millions of fans worldwide and also led to him being one of the most loved sharks on the show.
A <a href="https://www.benzinga.com/general/entertainment/25/03/44522293/shark-tank-poll-reveals-most-polarizing-star-is-it-mark-cuban">recent Benzinga poll</a> found Cuban to be the favorite shark with 40% of the vote. Ironically, he also tied at 32% of the vote with Kevin O'Leary for the least favorite shark.
Similar to Musk, Cuban could be a person that many either hate or love, with no middle ground. Many love Cuban's approach on "Shark Tank" of making quick deals and not giving other sharks time to propose deals. Others likely think it hurts the integrity of the show.
Cuban could be ruthless on "Shark Tank," but also showed a human side, often with deals made for products he didn't know but his daughters did, and making investments in entrepreneurs with good stories and a hard work ethic.
The study was conducted by Benzinga from July 1, 2025, through July 3, 2025. It included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 102 adults.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/entertainment/25/06/46042333/elon-musk-paid-1m-for-a-james-bond-car-it-was-found-in-a-100-storage-unit">Elon Musk Paid $1M For A James Bond Car — It Was Found In A $100 Storage Unit</a></li>
</ul>
Image created using pictures from Shutterstock.

Education

Entrepreneurship

Management

Success Stories

Exclusives

TSLA

Mark Cuban And Elon Musk Have Something In Common Beyond Their Billions

During the last three months, 5 analysts shared their evaluations of Certara (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $14.4, a high estimate of $18.00, and a low estimate of $11.00. This current average reflects an increase of 20.0% from the previous average price target of $12.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1751569371_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Certara is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sean Laaman</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$16.00</td>
<td>-</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$14.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$13.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$11.00</td>
<td>$13.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Certara. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Certara compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Certara's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Certara's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CERT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Certara analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Certara's Background</h2>
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.
<h3>Certara: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Certara displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 9.67%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Certara's net margin excels beyond industry benchmarks, reaching 4.47%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Certara's ROE stands out, surpassing industry averages. With an impressive ROE of 0.44%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Certara's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.3% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.28.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

CERT

What Analysts Are Saying About Certara Stock

In the latest quarter, 14 analysts provided ratings for Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>), showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">10</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $1088.0, along with a high estimate of $1225.00 and a low estimate of $975.00. Experiencing a 0.78% decline, the current average is now lower than the previous average price target of $1096.54. 
<img src="https://www.benzinga.com/files/images/story/2025/1751569345_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Costco Wholesale's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$1100.00</td>
<td>$1100.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$1060.00</td>
<td>$1075.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$1100.00</td>
<td>$1100.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1225.00</td>
<td>$1150.00</td>
</tr>
<tr>
<td>Laura Champine</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$1110.00</td>
<td>$1115.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1075.00</td>
<td>$1070.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$1042.00</td>
<td>$995.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$1100.00</td>
<td>$1100.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$1100.00</td>
<td>$1100.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$1100.00</td>
<td>$1100.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$1100.00</td>
<td>$1100.00</td>
</tr>
<tr>
<td>David Belinger</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Neutral</td>
<td>$975.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$1100.00</td>
<td>$1100.00</td>
</tr>
<tr>
<td>Laura Champine</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$1045.00</td>
<td>$1150.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Costco Wholesale. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Costco Wholesale compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Costco Wholesale's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Costco Wholesale's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/COST/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Costco Wholesale analyst ratings.</a>
<h2>Delving into Costco Wholesale's Background</h2>
Costco operates a membership-based, no-frills retail model predicated on offering a select product assortment in bulk quantities at bargain prices. The firm avoids maintaining costly product displays by keeping inventory on pallets and limits distribution expenses by storing its inventory at point of sale in the warehouse. Given its frugal cost structure, the firm is able to price its merchandise below that of competing retailers, driving high sales volume per warehouse and generating strong profits on thin margins. Costco operates over 600 warehouses in the United States and has over 60% share in the domestic warehouse club industry. Internationally, Costco operates about 280 warehouses, primarily in Canada, Mexico, Japan, and the UK.
<h3>Costco Wholesale: Delving into Financials</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Costco Wholesale's revenue growth over a period of 3M has been noteworthy. As of 31 May, 2025, the company achieved a revenue growth rate of approximately 8.02%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Staples sector.
Net Margin: Costco Wholesale's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 3.01%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Costco Wholesale's ROE stands out, surpassing industry averages. With an impressive ROE of 7.22%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.56%, the company showcases effective utilization of assets.
Debt Management: Costco Wholesale's debt-to-equity ratio is below the industry average at 0.3, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

COST

Assessing Costco Wholesale: Insights From 14 Financial Analysts

Analysts' ratings for Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) over the last quarter vary from bullish to bearish, as provided by 33 analysts.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">13</td>
<td align="right">15</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">7</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $135.97, a high estimate of $200.00, and a low estimate of $95.00. Observing a downward trend, the current average is 2.57% lower than the prior average price target of $139.56. 
<img src="https://www.benzinga.com/files/images/story/2025/1751569325_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of Advanced Micro Devices by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$152.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Ben Reitzes</td>
<td>Melius Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$175.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Ben Reitzes</td>
<td>Melius Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$175.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Harsh Kumar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Ruben Roy</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$132.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Sujeeva De Silva</td>
<td>Roth Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Mark Lipacis</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$144.00</td>
<td>$126.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$170.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Christopher Danely</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$120.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Tom O'Malley</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$130.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Mark Lipacis</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$100.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Tristan Gerra</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$140.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Matt Bryson</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Srini Pajjuri</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$150.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Harsh Kumar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Matthew Prisco</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Gary Mobley</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$140.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$121.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Hans Mosesmann</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Jay Goldberg</td>
<td>Seaport Global</td>
<td>Announces</td>
<td>Buy</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Ruben Roy</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$132.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$135.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Matt Bryson</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Stacy Rasgon</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$95.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Tom O'Malley</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$155.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Aaron Rakers</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Mark Lipacis</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$126.00</td>
<td>$147.00</td>
</tr>
<tr>
<td>Christopher Danely</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$110.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Advanced Micro Devices. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Advanced Micro Devices compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Advanced Micro Devices's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Advanced Micro Devices's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AMD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Advanced Micro Devices analyst ratings.</a>
<h2>Get to Know Advanced Micro Devices Better</h2>
Advanced Micro Devices designs a variety of digital semiconductors for markets such as PCs, gaming consoles, data centers, industrial, and automotive applications. AMD's traditional strength was in central processing units and graphics processing units used in PCs and data centers. Additionally, the firm supplies the chips found in prominent game consoles such as the Sony PlayStation and Microsoft Xbox. In 2022, the firm acquired field-programmable gate array leader Xilinx to diversify its business and augment its opportunities in key end markets such as data center and automotive.
<h3>Financial Milestones: Advanced Micro Devices's Journey</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3M period, Advanced Micro Devices showcased positive performance, achieving a revenue growth rate of 35.9% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Advanced Micro Devices's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 9.53%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Advanced Micro Devices's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.23%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Advanced Micro Devices's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.01%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Advanced Micro Devices's debt-to-equity ratio is below the industry average at 0.08, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Advanced Micro Devices: Insights From 33 Analyst Reviews

Deep-pocketed investors have adopted a bullish approach towards Goldman Sachs Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in GS usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 49 extraordinary options activities for Goldman Sachs Group. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 46% leaning bullish and 30% bearish. Among these notable options, 19 are puts, totaling $1,148,551, and 30 are calls, amounting to $2,691,877.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $590.0 to $850.0 for Goldman Sachs Group over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Goldman Sachs Group's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Goldman Sachs Group's whale activity within a strike price range from $590.0 to $850.0 in the last 30 days. 
<h3>Goldman Sachs Group Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751569302_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$34.85</td>
<td>$34.4</td>
<td>$34.65</td>
<td>$715.00</td>
<td>$806.9K</td>
<td align="right">326</td>
<td align="right">263</td>
</tr>
<tr>
<td>GS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/11/25</td>
<td>$19.6</td>
<td>$19.15</td>
<td>$19.59</td>
<td>$710.00</td>
<td>$385.8K</td>
<td align="right">371</td>
<td align="right">309</td>
</tr>
<tr>
<td>GS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$42.5</td>
<td>$41.85</td>
<td>$41.9</td>
<td>$640.00</td>
<td>$293.3K</td>
<td align="right">9</td>
<td align="right">70</td>
</tr>
<tr>
<td>GS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/25/25</td>
<td>$28.85</td>
<td>$28.25</td>
<td>$28.55</td>
<td>$710.00</td>
<td>$142.7K</td>
<td align="right">84</td>
<td align="right">55</td>
</tr>
<tr>
<td>GS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$25.6</td>
<td>$25.35</td>
<td>$25.35</td>
<td>$850.00</td>
<td>$139.4K</td>
<td align="right">175</td>
<td align="right">56</td>
</tr>
</tbody>
</table>

<h3>About Goldman Sachs Group</h3>
Goldman Sachs is a storied financial institution, founded in 1869 and best known for its role as a leading global investment bank. The firm has a sprawling reach across global financial centers and has been the leading provider of global merger and acquisition advisory services, by revenue, for the past 20 years. Since the global financial crisis, Goldman has expanded its offerings into more stable fee-based businesses like asset and wealth management, which comprised roughly 30% of post-provision revenue at the end of 2024. The bank holding company generates revenue from investment banking, global market making and trading, lending, asset management, wealth management, and a small and declining portfolio of consumer credit card loans.
After a thorough review of the options trading surrounding Goldman Sachs Group, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Goldman Sachs Group</h3>
<ul>
<li>Trading volume stands at 1,500,404, with GS's price up by 1.08%, positioned at $723.6.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 13 days.</li>
</ul>
<h3>Professional Analyst Ratings for Goldman Sachs Group</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $653.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Goldman Sachs Group with a target price of $592. 
&#x2A; An analyst from Evercore ISI Group persists with their Outperform rating on Goldman Sachs Group, maintaining a target price of $715. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Goldman Sachs Group, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

Check Out What Whales Are Doing With Goldman Sachs Group

Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Axsome Therapeutics, presenting an average target of $179.18, a high estimate of $200.00, and a low estimate of $150.00. Surpassing the previous average price target of $177.00, the current average has increased by 1.23%.
<img src="https://www.benzinga.com/files/images/story/2025/1751569300_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Axsome Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sean Laaman</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$190.00</td>
<td>-</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$186.00</td>
<td>$193.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$150.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Matthew Hershenhorn</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$185.00</td>
<td>-</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$180.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Cerena Chen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$162.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$193.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Andrew Tsai</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$200.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Axsome Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Axsome Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Axsome Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Axsome Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AXSM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Axsome Therapeutics analyst ratings.</a>
<h2>About Axsome Therapeutics</h2>
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
<h3>Unraveling the Financial Story of Axsome Therapeutics</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Axsome Therapeutics's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 61.95%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Axsome Therapeutics's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -48.91%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -107.81%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Axsome Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -10.2%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a high debt-to-equity ratio of 3.97, Axsome Therapeutics faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AXSM

Where Axsome Therapeutics Stands With Analysts

Whales with a lot of money to spend have taken a noticeably bearish stance on Intuitive Surgical.
Looking at options history for Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 11% of the investors opened trades with bullish expectations and 66% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $138,480 and 6, calls, for a total amount of $256,590.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $500.0 to $580.0 for Intuitive Surgical over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Intuitive Surgical's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Intuitive Surgical's significant trades, within a strike price range of $500.0 to $580.0, over the past month.
<h3>Intuitive Surgical Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751569298_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$39.3</td>
<td>$35.4</td>
<td>$37.45</td>
<td>$540.00</td>
<td>$74.9K</td>
<td align="right">179</td>
<td align="right">23</td>
</tr>
<tr>
<td>ISRG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/22/25</td>
<td>$20.5</td>
<td>$18.1</td>
<td>$18.0</td>
<td>$530.00</td>
<td>$70.2K</td>
<td align="right">0</td>
<td align="right">39</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$19.0</td>
<td>$18.0</td>
<td>$18.0</td>
<td>$535.00</td>
<td>$59.4K</td>
<td align="right">108</td>
<td align="right">34</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$14.9</td>
<td>$12.6</td>
<td>$13.0</td>
<td>$580.00</td>
<td>$42.9K</td>
<td align="right">162</td>
<td align="right">37</td>
</tr>
<tr>
<td>ISRG</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$53.3</td>
<td>$53.2</td>
<td>$53.3</td>
<td>$565.00</td>
<td>$42.6K</td>
<td align="right">7</td>
<td align="right">8</td>
</tr>
</tbody>
</table>

<h3>About Intuitive Surgical</h3>
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 9,500 da Vinci systems in hospitals worldwide, with more than 5,500 installations in the US and a growing number in emerging markets.
Following our analysis of the options activities associated with Intuitive Surgical, we pivot to a closer look at the company's own performance.
<h3>Current Position of Intuitive Surgical</h3>
<ul>
<li>With a volume of 702,924, the price of ISRG is up 0.72% at $544.47. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 19 days.</li>
</ul>
<h3>What The Experts Say On Intuitive Surgical</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $440.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Deutsche Bank has revised its rating downward to Sell, adjusting the price target to $440. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Intuitive Surgical with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

ISRG

Intuitive Surgical's Options: A Look at What the Big Money is Thinking

Investors with a lot of money to spend have taken a bearish stance on Wynn Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with WYNN, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 13 options trades for Wynn Resorts.
This isn't normal.
The overall sentiment of these big-money traders is split between 30% bullish and 53%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $70,750, and 12, calls, for a total amount of $671,809.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $70.0 to $115.0 for Wynn Resorts over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Wynn Resorts's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Wynn Resorts's whale activity within a strike price range from $70.0 to $115.0 in the last 30 days. 
<h3>Wynn Resorts 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751569293_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>WYNN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$19.15</td>
<td>$18.45</td>
<td>$19.0</td>
<td>$100.00</td>
<td>$190.0K</td>
<td>60</td>
<td align="right">100</td>
</tr>
<tr>
<td>WYNN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$35.4</td>
<td>$34.55</td>
<td>$35.4</td>
<td>$80.00</td>
<td>$106.2K</td>
<td>973</td>
<td align="right">30</td>
</tr>
<tr>
<td>WYNN</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$2.97</td>
<td>$2.67</td>
<td>$2.83</td>
<td>$95.00</td>
<td>$70.7K</td>
<td>343</td>
<td align="right">253</td>
</tr>
<tr>
<td>WYNN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$13.15</td>
<td>$12.4</td>
<td>$13.15</td>
<td>$92.50</td>
<td>$65.7K</td>
<td>1.6K</td>
<td align="right">50</td>
</tr>
<tr>
<td>WYNN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$1.75</td>
<td>$1.71</td>
<td>$1.71</td>
<td>$110.00</td>
<td>$63.6K</td>
<td>533</td>
<td align="right">447</td>
</tr>
</tbody>
</table>

<h3>About Wynn Resorts</h3>
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, and Encore Boston Harbor in Massachusetts opened June 2019. We expect the company to continue to build nongaming attractions in Macao over the next few years. We model Wynn's managed integrated resort in the United Arab Emirates to open in 2027. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and the US, respectively. In 2024, both the US and Macao were each 50% of total EBITDA.
In light of the recent options history for Wynn Resorts, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Wynn Resorts</h3>
<ul>
<li>Trading volume stands at 1,403,097, with WYNN's price up by 1.06%, positioned at $105.79.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 33 days.</li>
</ul>
<h3>What Analysts Are Saying About Wynn Resorts</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $109.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from JP Morgan has revised its rating downward to Overweight, adjusting the price target to $109. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Wynn Resorts options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

WYNN

Wynn Resorts's Options Frenzy: What You Need to Know

In the latest quarter, 4 analysts provided ratings for 4D Molecular Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for 4D Molecular Therapeutics, presenting an average target of $33.0, a high estimate of $44.00, and a low estimate of $25.00. This current average represents a 11.41% decrease from the previous average price target of $37.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1751569273_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive 4D Molecular Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$25.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$44.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$38.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to 4D Molecular Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of 4D Molecular Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of 4D Molecular Therapeutics's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of 4D Molecular Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/FDMT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on 4D Molecular Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About 4D Molecular Therapeutics</h2>
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
<h3>Key Indicators: 4D Molecular Therapeutics's Financial Health</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Challenges: 4D Molecular Therapeutics's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -50.0%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -342657.14%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): 4D Molecular Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -9.79% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): 4D Molecular Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -8.92%, the company may face hurdles in achieving optimal financial returns.
Debt Management: 4D Molecular Therapeutics's debt-to-equity ratio is below the industry average at 0.05, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FDMT

What 4 Analyst Ratings Have To Say About 4D Molecular Therapeutics

Southern Copper (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCCO#NYSE">SCCO</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Southern Copper, revealing an average target of $91.88, a high estimate of $105.00, and a low estimate of $79.00. A 4.12% drop is evident in the current average compared to the previous average price target of $95.83. 
<img src="https://www.benzinga.com/files/images/story/2025/1751569258_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Southern Copper. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rodolfo Angele</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$79.00</td>
<td>$83.50</td>
</tr>
<tr>
<td>Myles Allsop</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$105.00</td>
<td>-</td>
</tr>
<tr>
<td>Myles Allsop</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Rodolfo Angele</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$83.50</td>
<td>$84.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Southern Copper. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Southern Copper compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Southern Copper's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Southern Copper's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SCCO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Southern Copper analyst ratings.</a>
<h2>Unveiling the Story Behind Southern Copper</h2>
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. It generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. The company's geographical segments are The Americas, Europe, and Asia.
<h3>Key Indicators: Southern Copper's Financial Health</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Southern Copper's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 20.08%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Materials sector.
Net Margin: Southern Copper's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 30.3% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Southern Copper's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 10.1%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Southern Copper's ROA stands out, surpassing industry averages. With an impressive ROA of 4.91%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Southern Copper's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.83, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SCCO

A Glimpse Into The Expert Outlook On Southern Copper Through 4 Analysts

Gold Fields's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFI#NYSE">GFI</a>) short percent of float has risen 33.82% since its last report. The company recently reported that it has 6.44 million shares sold short, which is 0.91% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.06 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Gold Fields Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751569231_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Gold Fields has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Gold Fields's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Gold Fields's peer group average for short interest as a percentage of float is 4.12%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

What Does the Market Think About Gold Fields?

Tenet Healthcare's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) short percent of float has risen 47.37% since its last report. The company recently reported that it has 4.13 million shares sold short, which is 5.88% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.31 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Tenet Healthcare Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751569226_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Tenet Healthcare has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Tenet Healthcare's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Tenet Healthcare's peer group average for short interest as a percentage of float is 5.10%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

What Does the Market Think About Tenet Healthcare?

Fox's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOX#NYSE">FOX</a>) short percent of float has risen 12.88% since its last report. The company recently reported that it has 3.93 million shares sold short, which is 2.98% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.56 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Fox Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751569222_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Fox has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Fox's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Fox's peer group average for short interest as a percentage of float is 6.58%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Comments

Captivision

Captivision (CAPT) Options

Captivision (NASDAQ:CAPT) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL